NASDAQ:SUPN
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.'s revenue grew 8.6% in fiscal 2025 to $719.0M while operating margin fell to −8.7%, its lowest in 10 years. Free cash flow was $46.0M, 6.4% of revenue, and the diluted share count rose 0.9%.Summary generated from Supernus Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$719.0M
Revenue growth+8.6%
Revenue, 5-yr CAGR+6.7%
Gross margin89.6%
Operating margin−8.7%
Net margin−5.4%
ROICn/a
Return on equity−3.7%
Debt / equityn/a
Free cash flow$46.0M
FCF margin6.4%
Share count change+0.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 580 | 667 | 608 | 662 | 719 |
| Operating income | 86 | 46 | −5 | 82 | −62 |
| Net income | 53 | 61 | 1 | 74 | −39 |
| Free cash flow | n/a | 116 | 111 | 171 | 46 |
Recent filings
- 4Insider transaction report
Aug 14, 2026 - 4Insider transaction report
Aug 14, 2026 - 8-KOther events
Aug 3, 2026 - 8-KOther events
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KEntry into a material agreement
Aug 3, 2026 - 8-KResults of operations and financial condition
Jul 22, 2026